Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Astellas Pharma US 

1 Astellas Way

Northbrook  Illinois  60062  U.S.A.
Phone: 800-695-4321 Fax: n/a






Gilead (Seattle, WA) 

 Company News
Astellas Pharma US Release: New Enzalutamide Data To Be Presented In Late Breaking News Plenary Session At European Association Of Urology Congress 3/17/2015 10:04:13 AM
Astellas Pharma US And (BDO) Team Up To Offer Health Education At The 2015 CIAA Tournament Fan Fest 2/20/2015 1:37:13 PM
Astellas Pharma US Release: XTANDI™ (Enzalutamide) Now Approved In Europe For The Treatment Of Men With Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve 12/2/2014 9:16:16 AM
Medivation, Inc. (MDVN) And Astellas Pharma US Announce Phase 3 Study Of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy 10/31/2014 12:45:31 PM
Astellas Pharma US Teams Up With USA Rugby And Men's Health Network To Encourage Chicagoans To Answer The Challenge For Better Health 10/15/2014 8:13:43 AM
Brian McLellan Promoted To President Of Astellas Pharma US 10/2/2014 8:46:16 AM
Astellas Pharma US Appoints Karl Uhlendorf As Communications And Advocacy Director 6/24/2014 8:21:23 AM
Astellas Pharma US Release: Enzalutamide Data, Including Additional Results From The PREVAIL Trial, To Be Presented At Upcoming American Society of Clinical Oncology Annual Meeting 5/15/2014 7:04:42 AM
Astellas Pharma US Promotes Jeffrey Bloss To SVP Of Medical Affairs For The Americas 4/16/2014 6:35:08 AM
Astellas Pharma US Announces European Regulatory Submission For XTANDI® (enzalutamide) Capsules For Chemotherapy-Naive Metastatic Prostate Cancer 4/3/2014 9:23:22 AM